Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2002

View Archived Issues

David Pharmaceuticals changes name, advances cognitive compounds

Leptin gene therapy in rats fed a high-fat diet

The novel spin trap agent NXY-059 improves safety profile of tPA

Sevelamer prevents progressive coronary and aortic calcification in hemodialysis patients

Pharmacia submits NDA for eplerenone in Japan

NEO-339 improves attention deficits, learning and memory in animals

Schering AG acquires MAP Medical Technologies

ETC-642 phase I results consistent with preclinical studies

Millennium discontinues oral MLN-977 program

NitroMed presents novel CINOD that compares favorably with naproxen

Retinal neuroprotective effects demonstrated for (-)-MR-22 and flunarizine in rat model

Effects of S-23478 characterized in rat models, discussed at scientific meetings

PRO-542 active in all primary target cells, particularly effective in treatment-experienced patients

Antinociceptive effects of a selective NMDA NR2B subunit antagonist

SR-140333 effective in rat model of cutaneous inflammatory pain

Janssen presents novel MTP inhibitors and their use in lipoprotein disorders

New vitamin D analogues for skin disorders emerge from Roche R&D

Celltech identifies new inhibitors of LFA-1/ICAM-1 interaction

Selective alpha4 integrin inhibitors in early development at Celltech R&D

Fumagillin derivatives and their use in angiogenesis disorders

New antifungal compound isolated from Pseudallescheria cultures at Yamanouchi

Researchers at GSK describe new 5-HT6 ligands for depression, anxiety, etc.

FDA grants priority review for Pegasys combination treatment

Amgen completes acquisition of Immunex

Telik exercises option to develop compounds from Arizona Cancer Center collaboration

GTC Biotherapeutics completes rhATIII study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...